Effect of semaglutide versus placebo on cardiorenal outcomes by prior cardiovascular disease and baseline body mass index: Pooled post hoc analysis of SUSTAIN 6 and PIONEER 6.

18 However, this inconsistency was nominally significant, and a complementary analysis confirmed benefits of semaglutide versus placebo across a continuum of BMI values. 18 As the current pooled post hoc analysis included data for OW s.c. and OD oral semaglutide from the SUSTAIN 6 and PIONEER 6 CVOTs, respectively, our findings on consistent risk reduction of CV outcomes regardless of baseline BMI support previous conclusions.

also in 7,732 other papers